This is particularly relevant to CM-HUS pathology as approximately two thirds of patients harbor mutations in complement genes, including loss-of-function variants in complement regulators such as membrane cofactor protein (MCP), CFH, and complement factor I (CFI) (17, 18). Here, CFH is linked to cutaneous mastocytosis.